The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer
The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer
复制标题
DOI：
10.1016/s0959-8049(97)00154-8
复制
发表时间：
1997-09-01
影响因子：
8.4
通讯作者：
Reventos, J
中科院分区：
文献类型：
--
作者：
Esteller, M;Garcia, A;Reventos, J
本研究旨在探讨K-RAS癌基因激活在子宫内膜癌和子宫内膜不典型增生中的发生率及其临床病理意义。我们采用聚合酶链反应结合限制性片段长度多态性和基因组差异聚合酶链反应分析了55例子宫内膜癌中K-RAS点突变和基因扩增。K-RAS癌基因第12位密码子点突变发生率为14.5%（8/55）。此外，我们无法检测到任何K-RAS基因扩增在任何子宫内膜癌的研究。未发现K-RAS基因突变与发病年龄、组织学亚型、分化程度、临床分期或当前患者状态相关。我们的结论是，K-RAS突变是一个相对常见的事件在子宫内膜癌，但没有明确的预后价值。(C)1997年爱思唯尔科学有限公司
The aim of this study was to examine the prevalence and clinicopathological significance of K-RAS oncogene activation in endometrial carcinoma and atypical hyperplasia. We analysed K-RAS point mutation and gene amplification in 55 endometrial carcinomas using polymerase chain reaction associated with restriction fragment length polymorphism and genomic differential polymerase chain reaction. Point mutations at codon 12 of K-RAS oncogene were identified in 8 of 55 (14.5%) tumour specimens. In addition, we were unable to detect any K-RAS gene amplification in any of the endometrial carcinomas studied. No correlation was found between K-RAS gene mutation and age at onset, histological subtype, grade of differentiation, clinical stage or current patient status. We conclude that K-RAS mutation is a relatively common event in endometrial carcinomas, but with no clear prognostic value. (C) 1997 Elsevier Science Ltd.